Program

TBX4Life pre-conference symposium

The TBX4-syndrome, clinical features and exploring the path to a cure

co-organized by TBX4Life

12.00 - 12.45

Doors open and registration

12.45 – 13.00

Welcome and Introduction

13:00 – 13.30

Steve Abman (USA)

Keynote lecture: Pediatric Pulmonary Vascular Diseases spectrum and the place of TBX4

13.30 – 14.00

Mieke Kerstjens-Frederikse (NL)

Clinical lecture: Clinical and genetic aspects of TBX4 syndrome across the lifespan

14.00 – 14.30

Anne-Karina Perl (USA)

Translational lecture: Animal and human cell-based models: path to a cure for TBX4 syndrome

14.30 – 16.00

Cara Morgan (UK)

Mary Mullen (USA)
Maria J del Cerro (SP)
Rebeca Weldeghebreal (NL)

Expert panel members:
Shahin Moledina (UK)
Rolf Berger (NL)

Round table: Management of difficult TBX4 cases: case presentation and expert panel discussion

16.00 – 16.30

Break

16.30 – 17.00

Aurore Coulomb-L’Hermine (FR)

Clinical lecture: Pathology of developmental lung disorders

17.00 – 18.30

Martina Prapa (UK)

Olivier Danhaive (BE)

TBX4Life clinical working group workshop

18.30

Closing remarks

08.00 – 09.00

Registration, with coffee and croissants

09.00 – 09.10

Welcome and Opening

Rolf Berger

09.10 – 09.40

Pediatric PH beyond Niche: Exploring the True Scope of PH in Childhood

Mary Mullen

09.40 – 10.05

Clinical relevance of Genetic variations in neonatal and pediatric PH

Maria del Cerro

10.05 – 10.30

New insights in molecular mechanisms and new treatment targets

Soni Pullamsetti

10.30 – 11.00

Coffee break

What’s new from the WSPH 2024 pediatric task force (11.00-12.40 hrs)

11.00 – 11.25

Current definition and classification of pediatric PH useful in clinical practice?

Dunbar Ivy

11.25 – 11.50

Advancements in pharmacological treatment, a new treatment algorithm

Alessandra Manes

11.50 – 12.15

Current approach to surgical interventions, when and how?

Usha Krishnan

12.15 – 12.40

Referral for evaluation or listing for lung transplantation

Mary Mullen

12.40 – 14.00

Lunch

New insights in the world of neonatal PH (14.00-15.40 hrs)

14.00 – 14.25

A diagnosis of PH in the neonate and the role of “targeted echocardiography”

María Carmen Bravo

14.25 – 14.50

Diagnostic algorithm in “therapy-refractory” neonatal PH

Olivier Danhaive

14.50 – 15.15

Neonatal PH more than pulmonary arterial pressure: congenital diaphragmatic hernia, pulmonary vein stenosis and genetics

Usha Krishnan

15.15 - 15.40

A role for PAH targeted treatment in PH associated with BPD and other developmental lung diseases?

Jeff Fineman

15.40 - 16.10

Tea Break

New approaches to risk stratification in paediatric PH (16.10-17.25 hrs)

16.10 - 16.35

Prognosticators and Risk stratification in paediatric PH

Menno Douwes

16.35 - 17.00

Integration of genetics and -omics in risk stratification

Allen Everett

17.00 - 17.25

Should we use AI in prediction models in paediatric PH?

Chantal Lokhorst

18.30

Conference dinner at Prinsenhof Groningen

Martinikerkhof 23 Groningen

07.30 - 08.30

Registration

Old and new methods for monitoring paediatric PH (08.30-10.30 hrs)

08.30 - 08.55

The use of MRI in diagnosis and follow up

Shahin Moledina

08.55 - 09.20

Serial invasive hemodynamics for monitoring children with PAH

Julien Grynblat

09.20 - 09.45

Quantitative analysis of the pulmonary vasculature using CT-scan

Rosaria Ferreira

09.45 - 10.10

Unveiling pulmonary vascular remodeling: Synchrotron-based 3D-imaging

Karin Tran Lundmark

10.10 - 10.30

Accelerometry as treatment target and clinical relevant end-point?

Marc Jan Ploegstra

10.30 – 11.00

Coffee break

Challenging cases to challenge the experts (11.00-12.15 hrs)

11.00 - 11.25

Paediatric Pulmonary Arterial Hypertension: a clinical report with an unusual course

Sofia Rito

11.25 - 11.50

Complex Persistent Pulmonary Hypertension of the Newborn associated with Sertraline exposure

Joseph Pattathu

11.50 - 12.15

Pediatric Portopulmonary Hypertension: Unveiling Challenges in Diagnosis and Treatment

Manuela Lopes

12.15 - 13.30

Lunch

The elusive right heart in paediatric pulmonary hypertension (13.30-14.45 hrs)

13.30 - 13.55

Clinical assessment of RV performance and its interaction with the pulmonary vasculature

Mark Friedberg

13.55 - 14.20

The role of the right atrium in clinical assessment of PH in children and neonates

Paul Critser

14.20 - 14.45

Computational Modeling of the RV and pulmonary circulation: potential clinical applications in pediatric PH

Christobal Bertoglio

14.45 - 15.15

Tea Break

Work in progress in Paediatric and Neonatal Pulmonary Vascular Disease

15.15 - 15.40

How to move forward in Clinical trials in infants and children with PH

Steve Abman

15.40 - 16.10

RepPHyNe registry, the need for real world data on neonatal pulmonary hypertension

Cara Morgan

16.10 - 16.35

Will future PAH drugs ever be approved for neonates and children? Regulators, trials and registries

Maurice Beghetti

16.35 - 16.45

Discussion

Panel

16.45 - 17.00

Closure

Annabelle Barnes

Research participation: viewpoints from young people with pulmonary hypertension

Dafni Charisopoulou

Clinical Characteristics and Outcomes in a Contemporary Pediatric Eisenmenger’s Syndrome Population

Natalia Gallego-Zazo

Pulmonary arterial hypertension associated with variants in the TBX4 gene

Manolis Mavrogiannis

Inflammasomme in experimental pulmonary arterial hypertension, a natural history study

Emma Olson-Jackson

Outcomes of Transcatheter ASD Closure in Infants Less Than 6 kg with Developmental Lung Disease

Rebeca Weldeghebreal

High nlrp3 inflammasome expression in lungs from pediatric pulmonary arterial hypertension patients

Yannick Yung

Galectin-3 as a Prognostic Biomarker in Children with Pulmonary Hypertension